The Critical and Unexpected Role of a Methyl Group in Interleukin-17A Inhibitors

Interleukin-17 (IL-17) is a pro-inflammatory cytokine primarily secreted by Th17 cells. It plays a crucial role in the body’s immune defense against fungal and bacterial pathogens. However, an imbalance in IL-17 production can contribute to the development of autoimmune and inflammatory disorders. Therapeutic strategies targeting IL-17, such as blocking antibodies like secukinumab (Cosentyx), have been successfully developed. These antibodies are currently employed in the treatment of various conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. More recently, a small molecule inhibitor of IL-17, LY3509754, progressed to clinical trials but was halted during Phase 1 due to unfavorable hepatotoxicity. Two derivatives, compounds 7 and 8, did not advance to clinical trials due to safety concerns. These three compounds (7, 8, and the original lead compound, presumably implied) share a common difluoro substituent, which was hypothesized to be the cause of the observed safety issues. In subsequent structure-activity relationship (SAR) studies, replacing the difluoro substituent with a single methyl group (resulting in compound 9) unexpectedly led to a significant improvement in cellular activity. Furthermore, compound 9 exhibited a very low unbound fraction and reduced liver distribution, ultimately translating to high in vivo efficacy with a sufficient safety margin. This seemingly minor methyl substitution transformed the compound into a highly promising preclinical candidate (compound 9 ), now slated for further development. Co-development inquiries are welcome. Please contact us at [email protected] . Abstract Figure